Sentence examples for treated advanced from inspiring English sources

Pfizer said outside monitors concluded that the Phase 3 trial of the lung cancer treatment, figitumumab, in patients with previously treated advanced non-small cell lung cancer was unlikely to show that the drug was effective.

Ramucirumab either alone or in combination with paclitaxel (PTX) has been found to be safe and effective for patients with previously treated advanced gastric cancer.

We recently performed a phase 2 study of weekly nab-paclitaxel in patients with previously treated advanced NSCLC, finding promising activity and acceptable toxicity for this regimen.

We have now designed a randomized phase 3 intergroup study (J-AXEL, UMIN000017487) to examine the clinical benefit and safety of nab-paclitaxel compared to docetaxel in patients with previously treated advanced NSCLC.

This open-label, phase I study investigated the maximum tolerated dose (MTD), safety, efficacy, and pharmacokinetics (PK) of BI 2536 IV in combination with standard-dose pemetrexed in previously treated advanced or metastatic non small-cell lunon small-cell

A prospective randomised clinical trial was designed to assess the usefulness of postoperative radiotherapy (RT) in terms of loco-regional control and survival in patients with surgically treated advanced (stages III to IV) head and neck squamous cell carcinoma with negative margins and without extracapsular extension in positive neck nodes.

We sought to screen for additional predictive biomarkers in a retrospective clinical series of 226 cetuximab-treated advanced CRC patients and to look for hypothesis-generating hints of efficacy or resistance.

Low level of RRM1 in early-stage cancer patients treated with surgery only has been associated with reduced survival [ 32- 35], whereas low RRM1 expression in gemcitabine-treated advanced cancer patients has been associated with improved survival [ 6, 9].

In conclusion, we have established a dosing schedule for the combination of capecitabine and mitomycin C that is both well tolerated and effective for the treatment of patients with previously treated advanced/metastatic colorectal and gastric cancer.

This is in accordance with recently published data on similar patient groups with heavily pre-treated advanced colorectal cancer, reporting median overall survival ranging from 8.3 to 11.9 months [21, 23 25].

In conclusion, low dose, oral CTX, demonstrated significant efficacy in this patient with pre-treated advanced ovarian cancer.